Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Affibody CEO Describes Three-Year Growth Plan

Executive Summary

Sten Stovall chats with David Bejker, CEO of Solna, Sweden-based biotech Affibody AB, about development progress for the company's novel class of antibody mimetics, which he says have superior characteristics surpassing monoclonal antibodies (mAbs) and antibody fragments.



Related Companies